Saturday, October 3, 2026

USD/CNH Over 4% Down In The Last 21 Sessions

ViaNews Editorial Team

February 16, 2023

USD/CNH Over 4% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 4.33% for the last 21 sessions. At 06:06 EST on Thursday, 16 February, USD/CNH (USDCNH) is $6.86.

USD/CNH's yearly highs and lows, it's 0.213% up from its 52-week low and 0.131% down from its 52-week high.

News about

  • Eur/usd price analysis: bulls cheer triangle breakout to aim for 1.0780 hurdle. According to FXStreet on Tuesday, 14 February, "Even if the EUR/USD pair declines below 1.0680, the lower line of the triangle, close to 1.0650, could act as the last defense of the buyers.", "With this, the EUR/USD buyers are on the way to the 200-bar Simple Moving Average (SMA), around 1.0780 by the press time. "
  • Eur/usd price analysis: bearish channel, 200-hma challenge latest run-up. According to FXStreet on Tuesday, 14 February, "It's worth noting, however, that a convergence of the 200-Hour Moving Average (HMA) joins the top line of a one-week-old descending trend channel to offer a tough nut to crack for the EUR/USD bulls around 1.0780.", "Should the EUR/USD pair remains bearish past 1.0655, the odds of witnessing a slump toward January's low near 1.0485 can't be ruled out."
  • According to FXStreet on Tuesday, 14 February, "Nevertheless, any meaningful divergence from the expected readings should infuse some volatility in the markets and allow traders to grab short-term opportunities around the EUR/USD pair.", "Dhwani also outlines important technical levels to trade the EUR/USD pair: "Buyers need to find acceptance above the 1.0750 psychological barrier to build on the recovery from five-week lows of 1.0655. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com